Lonza Group Ag (OTCMKTS:LZAGY) Sees Significant Increase in Short Interest

Lonza Group Ag (OTCMKTS:LZAGY) saw a significant increase in short interest in the month of May. As of May 15th, there was short interest totaling 55,395 shares, an increase of 102.6% from the April 30th total of 27,348 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily volume of 159,592 shares, the short-interest ratio is currently 0.3 days.

Lonza Group Stock Down 0.6%

Lonza Group stock opened at $62.97 on Wednesday. The company has a quick ratio of 1.77, a current ratio of 2.24 and a debt-to-equity ratio of 0.42. Lonza Group has a one year low of $58.53 and a one year high of $73.85. The business’s fifty day moving average is $63.10 and its 200 day moving average is $65.85.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on LZAGY shares. Zacks Research raised Lonza Group from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 8th. Royal Bank Of Canada raised Lonza Group from a “hold” rating to a “moderate buy” rating in a research note on Wednesday, February 11th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

About Lonza Group

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.